Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

Global contraceptives market dominated by oral contraceptives and condoms

Industry Sector

Healthcare and Medical


14 November 2012


Mike King

Type of News


The global contraceptives market has been forecast to increase at a compound annual growth rate (CAGR) of 2.1% over the next six years, rising from a valuation of $10.2 billion in 2011, to hit a market value of $11.8 billion by 2018.

All sexually active women face the risk of unwanted/unplanned pregnancy right from the years spanning menarche to menopause. The unprecedented rate of population explosion has become a cause for grave concern the world over. Therefore, a keen interest in curbing the number of unintended pregnancies is one of the top priorities of governments in the developing and developed countries, alike.

Since hormonal contraception was approved in the 1960s many different treatments have been developed, but has the pill seen its glory days pass. The contraceptive market consists of short-term (oral contraceptives, patch, ring, injectables), long-term (IUD, implant) and permanent contraceptive options.

With the increasing number of women acquiring publicly-funded birth control, and a growing public awareness and acceptance, the contraceptives market is ever-growing.

The annual cost of usage within the contraceptives market was $113 in 2011, which grew from $104 in 2004, at a CAGR of 1.2%. This is expected to further increase to $125 in 2018, at a CAGR of 1.4% between 2011 and 2018. The growth rate can be attributed to factors such as the expected patent expiry of Mirena and Yaz. Through to 2018, CSD500, a condom manufactured by Futura Medical and licensed to Reckitt and Benckiser, is expected to strengthen the condom market.Contraceptives

The condom remains the only form of contraception to offer full protection against sexually transmitted diseases, and this doesn't look likely to change anytime soon. However, the CSD500 condom, manufactured by Futura Medical and licensed by Reckitt Benckiser, contains a pharmacologic dosage to treat erectile dysfunction, representing a development in the most stable contraceptive segment.

For more information on the global contraceptives market, see the latest research: Global Contraceptives Market

Follow us on Twitter @CandMResearch

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency


Change Currency


Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

December Discounted Prices: Contact us to ask about our special discounts available in December

For the last month in 2014 we are offering discounted prices on a selection of new reports. Please contact us on 00 44 (0) 203 0868600 or via email (click here to email) to ask about prices and special discounts.

Available during December and the run-up to Christmas; Discounted prices on a selection of our reports.

Find all the research at the best prices. Great promotions being offered during December!

We are offering our clients substantial savings on the best research available during December. Please contact us either via emailor by calling our team to discuss your specific research needs on Tel: 00 44 (0) 203 0868600. We look forward to being able to find you the research you require at good prices.


Contrast settings

Text size settings